 BOSTON, July 22, 2021 GLOBE NEWSWIRE -- X4 Pharmaceuticals, Inc. Nasdaq: XFOR, a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2021, and provide an update on recent business highlights, on August 3, 2021. 